+100%-

ME/CFS and FM Moments?

Taking it to the next level for ME/CFS and FM?

Taking it to the next level for ME/CFS and FM?

I think of “moments” as unusual events that suggest the tide may be turning for these common but sorely neglected diseases.

Health Rising has documented several possible ME/CFS “moments” over the past two years and now we have one for fibromyalgia.

The first ME/CFS moment was a big win for Ron Davis – one of the greatest grant recipients in all of medicine – that is, until he tried to get them for ME/CFS – and ran into roadblock after roadblock. One wonders if Davis’s big 2022 win indicates that grant funders are taking ME/CFS more seriously. On that note, the Congressionally Directed Medical Research Program ME/CFS recently put ME/CFS grants into the priority column – another possible “ME/CFS moment”.

Ron Davis’s ME/CFS Moment: The “Core Technology Disrupter” Gets a Win

In May of 2022, Health Rising reported that both Bateman Horne Center and Benjamin Natelson were up to their ears with work. After a dry spell, Natelson was suddenly scoring grant after grant and the BHC was up to its neck in clinical trials.

Is ME/CFS Having A Moment? An ME/CFS Researcher and an ME/CFS Clinic Go Gangbusters

Next, came probably the most astonishing moment yet. Perhaps the most single most backward and despised medical group in the entire country – the Mayo Clinic –  apparently had something of a come-to-Jesus moment – and actually asked MEAction to help them develop a better ME/CFS treatment program. That was surely a sign that things were changing.

We could slide the integration of ME/CFS into the CDC-funded ECHO program on treating long COVID into the ME/CFS moment category. That, after all, resulted in physicians across the country learning about both long COVID and other fatiguing illnesses (like ME/CFS). Getting the CARE for LONG COVID bill – which includes ME/CFS in it – would certainly constitute an ME/CFS moment as it would speed about $100 million into better education for doctors, treatment assessments, and patient registries for both diseases. Ditto with the strategic plan for ME/CFS that’s underway at the NIH. If that goes over well and ends up with better funding for ME/CFS – that would certainly qualify as an ME/CFS moment. We may be having ME/CFS moments coming out of our ears at some point…

Hanson ME/CFS Research Group Grant

First comes the big grant that the Hanson ME/CFS research Center for Enervating Neuroimmune Disease at Cornell just scored – a nice, large $9.5 million grant over five years.

One thing that made this grant so special was where it came from – one of the three NIH-funded ME/CFS research centers. This grant is further evidence that these centers work (and should be expanded). They’ve shown that given sufficient funds, ME/CFS researchers can produce meaningful results and that ME/CFS is not an impenetrable disease.

Considered by some to be a wastebasket disease not worth studying, these big, high-powered NIH-funded studies are proving that idea a lie. As Andrew Grimson, one of the Cornell researchers, said – they took a broad approach – and lo and behold, specific molecular targets popped out.

“We took a broad interdisciplinary approach, with the hope that we would find specific molecular changes in ME/CFS; now that we have found these changes, we can target our research on these changes and understand their impact, ultimately moving towards a cure,”

The grant will focus on three aspects.

Monocytes – Grimson’s NIH-funded study was eye-opening, indeed. Using a fine-tuned gene expression approach new to ME/CFS, Grimson’s results potentially turned our understanding of ME/CFS patients’ immunology on its head.

None of the usual suspects – the NK cells, T- or B-cells – popped out, instead it was monocytes – a cell we’ve hardly ever heard of in connection with ME/CFS. The amazing thing was how strongly they showed up – they were clearly leading the show – and that’s good news. Strong findings like that provide clarity – a clear angle of attack. Given all the disparate immune findings in ME/CFS, having one cell show up big time like that was good news indeed.

Move Over NK, T and B-cells. Are Monocytes the Real Problem in ME/CFS?

Muscle Biopsy – Next, a deep, deep, deep dive into the muscles. Anyone who’s had ME/CFS would be shocked, I would bet, if the muscles weren’t involved in a major way – yet they’ve never been examined as deeply as they should be. ME/CFS muscle research is a glaring need.

In this project, Ben Cosgrove, and Iwijn De Vlaminck, will use a new machine to take detailed gene expression analyses in different parts of the muscle tissue that could potentially locate the exact cells where things have gone haywire. They’ll also look at the gene expression in muscle fibers, blood vessels, and immune cells.

Exercise Study – You would have thought ,given all the fascinating exercise results from Hanson’s NIH-funded ME/CFS research studies, that an exercise study had to be in here somewhere – and it is.

Among other things, those studies found dramatic reductions in the production of metabolites and proteins in ME/CFS patients vs healthy controls. This study will analyze RNA released into blood plasma when cells die, before and after exercise, as people with ME/CFS respond abnormally – and adversely – to exercise. This study will further the protein work and further assess the effect of exercise on gene expression. They will also analyze the extracellular vesicles from platelets, neuronal cells, and blood vessel cells.

Update! – I got this wrong. Because the grant announcement never mentioned the NIH ME/CFS Centers I assumed this was a separate grant. It was not – this is the Centers grant and as such, while it is an excellent grant, it was expected – and thus does not constitute an ME/CFS moment. 🙁

Fibromyalgia’s Moment

Further research is needed, but this offers hope to the millions of people with fibromyalgia that an effective treatment could be found in the relatively near future – Dr. Craig Bullock, Research Discovery and Innovations Lead at Versus Arthritis.

Fibromyalgia is potentially in the midst of its own paradigm-changing moment. It all started with Andersson and Goebel’s 2021 stunning study, “Passive transfer of fibromyalgia symptoms from patients to mice“, which found that giving mice IgG antibodies basically gave them fibromyalgia – suggesting that fibromyalgia is an autoimmune disease. The consistency of the findings even surprised the researchers on the team. Andreas Goebel said:

 “When I initiated this study in the UK, I expected that some fibromyalgia cases may be autoimmune. But David’s team have discovered pain-causing antibodies in each recruited patient. The results offer amazing hope that the invisible, devastating symptoms of fibromyalgia will become treatable.”

That was just the beginning. Fibromyalgia has primarily been thought to be a central nervous system disease, but when the researchers looked deeper, they couldn’t find any evidence that antibodies had made their way to the central nervous system. Instead, they were concentrated and presumably attacking the major sensory processing center outside the spinal cord – the dorsal root ganglia. Suddenly, fibromyalgia was looking more like a disease of the periphery than a disease of the central nervous system. The fact that the study involved two separate FM groups – one from the UK and one from Sweden – further buttressed its findings.

Something in the Blood II: Long-COVID / Fibromyalgia Autoimmune Connection Found

The Gist

  • “Moments” are signs that a disease may be turning a corner. We’ve documented several possible  ME/CFS moments – Ron Davis’s big grant, a high workload for the Bateman Horne Center, Ben Natelson’s string of grants after a dry spell, the Mayo Clinic coming to MEAction to help them treat ME/CFS patients better. 
  • Now comes two possible moments – one for ME/CFS and one for fibromyalgia. 
  • The ME/CFS moment involves an immense grant that Maureen Hanson and her ME/CFS research got. It’s significant because it’s so large and because it grew out of NIH-funded ME/CFS research center work, and thus demonstrates how effective these research centers can be (and why we need more of them). 
  • The grant will have three thrusts. One will follow up on the potentially ground-changing finding that it’s monocytes – not NK cells, T or B-cells – that are at the heart of the immune dysfunction in ME/CFS.
  • Another will use new technology to uncover – on a cellular basis – where the muscles have been impacted in ME/CFS. The third will assess the effects of exercise on gene expression.
  • The FM “moment” involves another potentially paradigm-changing study that could potentially turn the world of FM research and treatment on its head. This study will probe more deeply into the possibility that FM is an autoimmune disease caused by antibodies attacking the central sensory processing center (the dorsal root ganglia) leading to the spinal cord. A successful outcome would open up a wide range of treatment options never thought before to apply to FM. 
The findings stunned the fibromyalgia world, but the authors didn’t rest on their laurels. Instead, they produced a series of review papers revolving around their finding in FM and other pain conditions. In March 2022, in “The autoimmune aetiology of unexplained chronic pain“, they noted that similar IgG transfers had produced similar results in complex regional pain syndrome, chronic post-traumatic limb pain, and non-inflammatory joint pain. Interestingly, the antibodies clustered in different areas in different conditions.

Next, they convened a group of 29 stakeholders (including 3 patients/caregivers) and produced a research strategy for fibromyalgia. Dozens of research projects were assessed. Of the top five recommendations, three involved antibodies.

Then in October 2022, Andersson and Goebel (and Schofield) argued in, “The biology of symptom-based disorders – time to act“, that “symptom-based disorders are… very common, including pain and fatigue disorders, functional gastrointestinal and respiratory disorders” and “cause far greater disability than diseases where signs are prominent.” They urged funders to pour “resources into exploring the role of ‘invisible’, functional, non-inflammatory autoantibodies in symptom-based disorders”.

Andersson hit pay dirt this month when he won the Sir Jules Thorn Award for Biomedical Research, giving him and his co-investigators (including Goebel) £1,699,572 ($2,100,000) over five years.

Stating that, “These insights will fundamentally change future research and clinical management of FMS“, the award was very clear on the tremendous possibilities present. In an attempt to find a treatment target and biomarker, Andersson et al. will identify which molecules the patients’ autoantibodies are binding to (i.e. attacking). He will also dig deeper into what’s going on with the neurons that relay sensory information to the central nervous system and see how all this affects the central nervous system.

Time will tell if these are moments or not. Are the Ron Davis and Maureen Hanson awards harbingers of more funding? (Will Ian Lipkin and his peroxisomes get the next big grant?) Will the FM award end up reshaping how we think of fibromyalgia and open new treatment possibilities? Time will tell.

Support the Website That Brings You the News!

GIVE A ONE-TIME DONATION


GIVE MONTHLY



HEALTH RISING IS NOT A 501 (c) 3 NON-PROFIT
A BIG thanks to the 320 people who helped make Health Rising's fundraising drive a success!

Stay Up to Date with ME/CFS, Long COVID and Fibromyalgia News

Get Health Rising's free blogs featuring the latest findings and treatment options for the ME/CFS, long COVID, fibromyalgia and complex chronic disease communities. 

Thanks for subscribing! :)

Pin It on Pinterest

Share This